For most patients with non-muscle-invasive bladder cancer (NMIBC) the survival rate is favourable.
However, decreasing recurrence and progression rates remains an important goal. Which new developments are simmering and may become part of the clinical practice armamentarium soon? Will these techniques improve diagnosis? Will they improve the ability to predict the risk of recurrence and progression and ultimately increase survival rates?
In this session, John Kelly will explore novelties in diagnosis, including genetics and biomarkers, and Paola Gontero will elaborate on the role of re-TUR.
In the second part of the session, the focus will be on the future of high-risk NMIBC, particularly in patients who need to be treated when BCG is not available.
What is their best option: surgery or new agents and devices? Piotr Chlosta and Joan Palou will have a debate.